<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324268</url>
  </required_header>
  <id_info>
    <org_study_id>AK002-017</org_study_id>
    <nct_id>NCT04324268</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneously Administered Lirentelimab (AK002) in Adult Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allakos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allakos, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-center study to evaluate safety, tolerability, and bioavailability&#xD;
      of subcutaneously administered lirentelimab (AK002) in adult healthy volunteers. Subjects&#xD;
      will receive a single dose of intravenous AK002 or subcutaneous lirentelimab (AK002) assigned&#xD;
      in a double-blind, randomized fashion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Actual">February 10, 2021</completion_date>
  <primary_completion_date type="Actual">February 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subcutaneous cohorts will be assigned in a double-blind, randomized, placebo-controlled manner. IV cohorts will be open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of lirentelimab (AK002) administered subcutaneously by evaluating adverse events assessed using the CTCAE version 5</measure>
    <time_frame>Day 0 (baseline) to Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, including bioavailability, of lirentelimab (AK002) administered subcutaneously</measure>
    <time_frame>Day 0 (baseline) to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of lirentelimab (AK002) SC formulation as measured by changes in absolute peripheral blood counts of esoinophils</measure>
    <time_frame>Day 0 (baseline) to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of lirentelimab (AK002) SC formulation relative to lirentelimab (AK002) IV by analyzing the area under the serum AUC</measure>
    <time_frame>Day 0 (baseline) to Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Study Conducted in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC 0.3 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single dose of 0.3 mg/kg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC 1 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC 3 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC 5 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single dose of 5 mg/kg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV 1 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single dose of 1 mg/kg of lirentelimab (AK002) administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV 3 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV 3 mg/kg of lirentelimab (AK002) (Priming)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single dose of 3 mg/kg of lirentelimab (AK002) administered intravenously from an IV bag prepared with extra volume for priming IV set.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC 300 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single dose of 300 mg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC 450 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a total of 450 mg of lirentelimab (AK002), administered as two separate subcutaneous injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lirentelimab (AK002)</intervention_name>
    <description>Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.</description>
    <arm_group_label>IV 1 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>IV 3 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>IV 3 mg/kg of lirentelimab (AK002) (Priming)</arm_group_label>
    <arm_group_label>SC 0.3 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>SC 1 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>SC 3 mg/kg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>SC 300 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>SC 450 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>SC 5 mg/kg of lirentelimab (AK002)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provided written informed consent.&#xD;
&#xD;
          2. Male or female aged ≥18 and ≤65 years at the time of signing the ICF.&#xD;
&#xD;
          3. Determined by the Investigator to be in good health as documented by medical history,&#xD;
             vital signs, physical examination, laboratory assessments, ECG, and by general&#xD;
             observations.&#xD;
&#xD;
          4. Subjects must weigh at least 50 kg and have a BMI between 18 g/m2 and 30 kg/m2,&#xD;
             inclusive.&#xD;
&#xD;
          5. Negative urine drug screen at Screening.&#xD;
&#xD;
          6. Subjects must have the ability and willingness to attend the necessary visits to the&#xD;
             study center and the ability to communicate effectively with the study site personnel.&#xD;
&#xD;
          7. Negative screening ova and parasite test.&#xD;
&#xD;
          8. Female subjects must be either post-menopausal for at least 1 year with FSH level &gt;40&#xD;
             IU/mL at Screening or surgically sterile (tubal ligation, hysterectomy, or bilateral&#xD;
             oophorectomy) for at least 3 months, or if of childbearing potential, have a negative&#xD;
             pregnancy test and agree to use dual methods of contraception, or abstain from sexual&#xD;
             activity from Screening until the end of the study, or for 120 days following the last&#xD;
             dose of study drug, whichever is longer.&#xD;
&#xD;
          9. Male subjects with female partners of childbearing potential must agree to use a&#xD;
             highly effective method of contraception from Screening until the end of the study or&#xD;
             for 120 days following the last dose of study drug, whichever is longer. All fertile&#xD;
             men with female partners of childbearing potential should be instructed to contact the&#xD;
             Investigator immediately if they suspect their partner might be pregnant (e.g., missed&#xD;
             or late menstrual period) at any time during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Peripheral blood absolute eosinophil count &gt;300/µL.&#xD;
&#xD;
          2. Known hypersensitivity to any constituent of the study drug.&#xD;
&#xD;
          3. Women who are pregnant, breastfeeding, or planning to become pregnant while&#xD;
             participating in the study.&#xD;
&#xD;
          4. Presence of abnormal laboratory values considered to be clinically significant by the&#xD;
             Investigator.&#xD;
&#xD;
          5. Any disease of condition (medical or surgical) which, in the opinion of the&#xD;
             Investigator, would place the subject at increased risk.&#xD;
&#xD;
          6. History of malignancy except carcinoma in situ in the cervix, early stage prostate&#xD;
             cancer, or non-melanoma skin cancers.&#xD;
&#xD;
          7. Treatment with chemotherapy or radiotherapy in the preceding 6 months.&#xD;
&#xD;
          8. Treatment for a helminthic parasitic infection within 6 months of screening.&#xD;
&#xD;
          9. Use during the 30 days before Screening (or 5 half-lives, whichever is longer) or use&#xD;
             during the Screening period of omalizumab, dupilumab, systemic immunosuppressive&#xD;
             drugs, or systemic corticosteroids, except if receiving as part of a premedication&#xD;
             protocol.&#xD;
&#xD;
         10. Vaccination with live attenuated vaccines within 30 days prior to initiation of&#xD;
             treatment in the study, during the treatment period, or vaccination expected within 5&#xD;
             half-lives (4 months) of study drug administration.&#xD;
&#xD;
         11. Positive hepatitis serology results, except for vaccinated subjects or subjects with&#xD;
             past but resolved hepatitis, at Screening.&#xD;
&#xD;
         12. Positive HIV serology results at Screening.&#xD;
&#xD;
         13. Alcohol, drug, or other substance abuse or dependence.&#xD;
&#xD;
         14. Any other reason that, in the opinion of the Investigator or Medical Monitor, makes&#xD;
             the subject unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Rasmussen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Allakos, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

